ASCO 2023

ASCO 2023
June 02-06, 2023
Chicago, IL

American Society of Clinical Oncology.

Explore more information for Gilead Oncology therapies
Results (15)

ARC-7: Randomized Phase 2 Study of Domvanalimab + Zimberelimab +/- Etrumadenant vs Zimberelimab in First-Line, Metastatic, PD-L1-High Non-Small Cell Lung Cancer (NSCLC)

Final Overall Survival Analysis from the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan in Patients with HR+/HER2- Metastatic Breast Cancer

A Phase 2 Study of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ELEVATE HNSCC) (TiP)

TROPiCS-03, A Phase 2 Basket Study of Sacituzumab Govitecan in Patients with Metastatic Solid Tumors: Early Analysis in Patients with Advanced/Metastatic Endometrial Cancer

STAR-221: A Randomized, Open-Label, Multicenter, Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Previously Untreated, Locally Advanced, Unresectable or Metastatic Gastric, Gastroesophageal Junction and

Efficacy of Sacituzumab Govitecan in Locally Advanced or Metastatic Urothelial Cancer by Trophoblast Cell Surface Antigen 2 (Trop-2) Expression

ARC-10: A Phase 3 Study to Evaluate Zimberelimab + Domvanalimab versus Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non–Small Cell Lung Cancer

A Phase 2 Randomized Study of Magrolimab Combination Therapy in Adult Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE-TNBC) (TiP)

Trop-2 mRNA Expression and Association with Clinical Outcomes with Sacituzumab Govitecan in Patients with HR+/HER2– Metastatic Breast Cancer: Biomarker Results from the Phase 3 TROPiCS-02 Study

ASCENT-05/OptimICE-RD (AFT-65): Phase 3, Randomized, Open-label Study of Adjuvant Sacituzumab Govitecan + Pembrolizumab vs Pembrolizumab ± Capecitabine in Patients with TNBC and Residual Disease after Neoadjuvant Therapy and Surgery

Safety Analysis by UGT1A1 Status of TROPHY-U-01 Cohort 1, a Phase 2 Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Cancer Who Progressed After Platinum-Based Chemotherapy and a Checkpoint Inhibitor

TROPHY-U-01 Cohort 4: Sacituzumab Govitecan in Combination with Cisplatin as First-Line Therapy, Followed by Maintenance Avelumab + Sacituzumab Govitecan or Zimberelimab + Sacituzumab Govitecan in Patients

STAR-121: A Phase 3, Randomized Study of Domvanalimab and Zimberelimab in Combination with Chemotherapy vs Pembrolizumab and Chemotherapy in Patients with Untreated Metastatic Non-Small CellLlung Cancer with No Actionable Gene Alterations (TiP)

VELOCITY-Lung: A Phase 2 Study Evaluating Safety and Efficacy of Domvanalimab (Dom) + Zimberelimab (Zim) + Sacituzumab Govitecan (SG), or Etrumadenant (Etruma) + Dom + Zim, or Etruma + Zim in Patients with Treatment-Naïve Metastatic

A Phase 2 Multi-Arm Study of Magrolimab in Combination with Docetaxel in Patients with Locally Advanced or Metastatic Solid Tumors (ELEVATE Lung and UC) (TiP)